Ratio Wealth Group’s Traws Pharma TRAW Stock Holding History

Ratio Wealth Group’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-133	Closed	-$23.3K	–	52
2020 Q4	$23.3K	Buy	+133	New	+$15.4K	0.01%	49

Other funds holding TRAW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Ratio Wealth Group's TRAW Position: Q1 2021 in Review

Ratio Wealth Group sold out of Traws Pharma (TRAW) in Q1 2021, closing a stake of 133 shares — an estimated $23.3K sold.

Ratio Wealth Group first reported a position in TRAW in Q4 2020 and held it in 1 quarter. The position peaked at $23.3K in Q4 2020. 56 funds tracked by Wall St. Rank hold TRAW as of Q1 2021.

Ratio Wealth Group reported no remaining Traws Pharma position as of Q1 2021 after selling out during the quarter.
Ratio Wealth Group sold 133 Traws Pharma shares in Q1 2021, an estimated $23.3K.
Ratio Wealth Group first reported a position in Traws Pharma in Q4 2020 and held it in 1 quarter.
Ratio Wealth Group's Traws Pharma position peaked at $23.3K in Q4 2020.
56 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2021.

Based on Ratio Wealth Group's 13F filing for Q1 2021, filed 27 Mar 2023.